Showing results (1281-1290 of 1,708) with videos related to
Sort By:
Pageof 171
Heart (British Cardiac Society)|May 22, 2021
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery diseaseGilles R Dagenais, Leanne Dyal, Jacqueline J Bosch, et al.Annals of the Rheumatic Diseases|September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL SurveillanceChristina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.Journal of the American College of Cardiology|February 27, 2016
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus ClopidogrelJacob A Doll, Megan L Neely, Matthew T Roe, et al.American Heart Journal|December 9, 2008
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosisShinya Goto, Deepak L Bhatt, Joachim Röther, et al.The American Journal of Medicine|October 3, 2020
Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and HypertensionCharles Faselis, Phillip H Lam, Michael R Zile, et al.Circulation. Cardiovascular Quality and Outcomes|March 16, 2019
Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction CareNihar R Desai, Jacob A Udell, Yongfei Wang, et al.JACC. Cardiovascular Interventions|August 24, 2019
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCIStefan H Hohnloser, Philippe Gabriel Steg, Jonas Oldgren, et al.Journal of the American College of Cardiology|May 27, 2014
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3George L Bakris, Raymond R Townsend, Minglei Liu, et al.Vascular Medicine (London, England)|June 20, 2012
An evidence-based score to detect prevalent peripheral artery disease (PAD)Sue Duval, Joseph M Massaro, Michael R Jaff, et al.European Heart Journal. Cardiovascular Pharmacotherapy|April 24, 2024
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observationShaun G Goodman, Philippe Gabriel Steg, Michael Szarek, et al.Pageof 171